Introduction
Pitavastatin is the first totally synthetic 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor. Experiments with guinea pigs demonstrated that total cholesterol and TG levels were reduced by enhancing expression of the hepatic low-density lipoprotein (LDL) receptor and suppressing secretion of very low-density lipoprotein (VLDL) 1) . Pharmacokinetic studies have suggested that pitavastatin is only slightly metabolized by the cytochrome P450 (CYP) system 2, 3) , and its lactone form had no inhibitory effect on the CYP3A4-mediated metabolism of concomitantly administered drugs 2, 3) . In the clinical setting, pitavastatin lowered total cholesterol and LDL cholesterol levels by 28% and 40%, respectively 4) . Atorvastatin is a highly efficacious HMG-CoA reductase inhibitor currently undergoing worldwide clinical development. Atorvastatin (10-80 mg) was shown to lower LDL cholesterol levels by 41% to 61% in a dose response study in hypercholesterolemic patients and has also been shown to reduce levels of triglycerides (TG) by up to 46% in hypertriglyceridemic patients 5, 6) . Among patients who have recently had an acute coronary syndrome, atorvastatin provided greater protection against death or major cardiovascular events 7) . In addition, intensive lipid-lowering treatment with atorvastatin ameliorated the progression of coronary atherosclerosis compared with treatment with pravastatin 8) . The purpose of this study was to determine the efficacy and safety of a low dose of pitavastatin compared with atorvastatin treatment in patients with primary hyperlipidemia.
Methods

Study Design
A 12-week open label and non-randomized study was performed at five primary care centres in Shizuoka, Japan. Eligible patients were men and women who were at least 18 The atorvastatin group and pitavastatin group comprised different patients. As different doctors selected the patients, the study subjects were not recruited consecutively. Previous lipid-lowering medications were discontinued for at least 4 weeks. Daily calorie intake totaled between 1,400 and 1,800 depending on the subject's height, and cholesterol intake was 300 mg/day. A dietary baseline phase was followed by a treatment phase in which patients received pitavastatin 1 mg or atorvastatin 10 mg for 12 weeks. At the baseline dietary phase, lipid profiles were obtained to determine eligibility. Patients included in the study were those with a plasma LDL cholesterol level above 140 mg/dl and a plasma TG level below 400 mg/dl. Patients were ineligible if they were pregnant or had familial hyperlipoproteinemia, acute phase coronary artery disease, active liver disease, hepatic or renal dysfunction, or uncontrolled hypertension. Study participants could not concurrently take drugs known to affect lipid levels or known to interact with the study medication. The objectives and implications of the study were explained to the patients according to the Declaration of Helsinki, and written informed consent was obtained from each patient prior to their participation in the study.
Lipid Measurements and Calculations
All lipid measurements were obtained following a 12-hour overnight fast. Laboratory measures included total cholesterol, high density lipoprotein (HDL) cholesterol, and TG levels. The concentration of LDL cholesterol was estimated by the formula (LDL cholesterol total cholesterol -HDL cholesterol TG 0.2) 9) . Serum cholesterol and TG levels were measured by enzymatic assay. HDL cholesterol levels were measured enzymatically with a kit from Daiichi Kagaku Co. Ltd. (Tokyo, Japan). Patients were divided into a hyperlipidemia type a group (plasma TG 150 mg/dl and LDL cholesterol 160 mg/dl) and a hyperlipidemia type b group (plasma TG 150 mg/ dl and LDL cholesterol 160 mg/dl).
At each visit, patients were asked about their health status and adverse events, and investigators assessed these events in terms of intensity, duration, relation to study medication, and clinical outcome. A clinical laboratory evaluation (routine hematology and blood chemistry testing) was done at screening and 12 weeks, while evaluations for safety (alanine aminotransferase, aspartate aminotransferase and creatine phosphokinase) were done during the study period. Adverse events were recorded at each visit. Associated adverse events were those the investigator judged definitely, probably or possibly related to treatment as well as those for which the investigator indicated an unknown relationship to treatment or insufficient available information for evaluation.
Statistical Analysis
Data were expressed as the mean standard deviation (for normally distributed variables) and a percentage (for categorical variables). Statistical analysis was performed with the Student t test for paired or unpaired data where appropriate. Differences in frequency were tested by 2 analysis. Because the distribution of TG was highly skewed, the natural logarithm of TG [In(TG)] was used for statistical tests. Differences were considered statistically significant at a value of p 0.05.
Results
Clinical Characteristics
There were no significant differences in age, sex, and body mass index between the pitavastatin group and the atorvastatin group ( Table 1) . Risk factors and complications did not differ between the two groups either.
Lipid Values
Changes in serum lipid and lipoprotein concentrations are listed in Table 2 . Total cholesterol, LDL cholesterol, HDL cholesterol and TG levels at baseline did not differ between the two groups. At follow-up, there were no significant differences in total cholesterol, LDL cholesterol and HDL cholesterol levels between the groups. The level of TG at follow-up was higher in the pitavastatin group than atorvastatin group (p 0.01). That of HDL cholesterol did not change during treatment in the pitavastatin group. Changes in total cholesterol, LDL cholesterol, and HDL cholesterol levels did not differ between the two groups. The change in TG was higher in the atorvastatin group than pitavastatin group (p 0.05).
In patients with hyperlipidemia type a, there were no significant differences in total cholesterol, LDL cholesterol, HDL cholesterol, and TG levels at baseline between the two subgroups ( Table 3 ). The TG level at follow-up was lower in the atorvastatin subgroup than pitavastatin subgroup (p 0.01). Changes in HDL cholesterol and TG levels were higher in the atorvastatin subgroup (p 0.01). In patients with hyperlipidemia type b, there were no significant differences in total cholesterol, LDL cholesterol, HDL cholesterol, and TG levels at baseline and follow-up between the two subgroups ( Table 4) . Changes in total cholesterol, LDL cholesterol, HDL cholesterol and TG levels did not differ between the two subgroups.
Safety
All patients completed the 12-week study. Treatment with atorvastatin 10 mg or pitavastatin 1 mg was well tolerated. None of the serious adverse events (hospitalization, cancer, overdose, and death) were considered associated with treatment. There were no adverse events in the study indicative of musculoskeletal, renal, or hepatocellular toxicity. No patient had an elevation of the creatine kinase level that was greater than 3 times the upper limit of normal. (14) 4 (6) (72) 7 (10) 4 (6) 1 (1) 0 Values are expressed as the mean SD or number (%) of patients. BMI body mass index 
Discussion
Cholesterol-Lowering Effects
It is widely recognized that hyperlipidemia, especially hypercholesterolemia, is a critical risk factor for the development/worsening of atherosclerosis. Pitavastatin inhibited hepatic cholesterol synthesis 18 times more strongly than pravastatin and 2.8 times more strongly than simvastatin in rats. It produced 23% to 33% and 38% to 47% reductions in total and LDL cholesterol levels, respectively, in patients with hyperlipidemia in a clinical trial [10] [11] [12] [13] [14] [15] [16] . Levels of LDL receptor mRNA and HMG-CoA mRNA were significantly higher in Hep G2 cells treated with pitavastatin than those treated with atorvastatin 17) . Although several results obtained in experimental animals support the hypothesis that the increased hepatic LDL receptor activity brought about by reductase inhibitors may be beneficial for the clearance of LDL cholesterol, in human subjects, little evidence of this has been obtained. This study showed no significant differences in reductions of total and LDL cholesterol levels between the pitavastatin group and the atorvastatin group. Further randomized studies will be necessary to clarify our results.
Placebo controlled studies with many of the approved statins (atorvastatin, pravastatin, fluvastatin, simvastatin, and lovastatin) have demonstrated a decrease in cardiac morbidity with their use 18) . Atorvastatin was the most powerful compound in this group, improving the patients' health and life expectancy 19) . Lower doses of statins generally produced less cholesterol lowering 19) . However, similar cholesterol-lowering effects were achieved by pitavastatin 1 mg and atorvastatin 10 mg. The maximum gain in life expectancy was achieved with atorvastatin, which also had a lower net cost than lovastatin, pravastatin, and simvastatin 20) . Pitavastatin may provide a potentially better therapeutic choice for lipid-modifying therapy than other currently available statins.
Over the past two decades, clinical and experimental studies have suggested that statin therapy, especially with atorvastatin, directly produces significant alterations in various cell populations that comprise atherosclerotic vascular lesions 19) . Pleiotropic actions of statins have also been suggested by their salutary effects in a wide range of diseases 21) . For the most part, a generalized antiinflammatory action has been invoked as an explanation. Pitavastatin inhibited the mRNA expression of interleukin-8 and monocyte chemoattractant protein-1 in human umbilical vein endothelial cells to a greater extent than did atorvastatin 22) . It is well recognized that a reduction in the LDL cholesterol level is associated with a stabilization of lipid plaques and prevention of coronary vascular events. There is a possibility that pitavastatin improves the prognosis of cardiovascular disease as much as atorvastatin, but confirmation of this has yet to be accomplished in a large-scale clinical trial.
Triglyceride and Statin
No significant difference in the change in TG was observed between the two type b subgroups. However, a significant reduction in the level of TG was observed in the type a subgroup treated with atorvastatin. The mechanisms of the change in TG have not been clarified. Type a patients have been shown to exhibit high concentrations of large and intermediate LDL subfractions as compared with type b patients 23) . It was suggested that the atorvastatin-induced reduction in total LDL mass affected the large and intermediate density LDL subfractions in patients with type a hyperlipidemia 24) . Moreover, a receptor-mediated reduction in large and intermediate-density LDL subfractions was observed in patients with type a hyperlipidemia after atorvastatin treatment 24) . Pravastatin and fluvastatin did not seem to significantly influence the distribution of LDL particles in type a or b hyperlipidemic patients 25, 26) . Few reports have shown whether pitavastatin induces changes in LDL subfractions. Although type a patients had normal TG levels at baseline, they exhibited a minor but significant decrease after atorvastatin treatment 24, 27) . In addition, atorvastatin might affect plasma TG levels through either increased removal of TG rich-lipoproteins or decreased hepatic secretion of apo B particles such as VLDL in those subjects with excessive production rates or both 28) . Compared with previous reports, the change in TG levels in this study was small. Park et al. suggested a 30% reduction in levels of TG among patients treated with pitavastatin 2 mg 29) . In contrast, the reduction produced by pitavastatin 1 mg was small (8%) 30) . These results were related to differences in age, BMI, and patient selection. Moreover, atorvastatin 10 mg may be more active against TG than pitavastatin 1 mg. A dose-dependent change in the level of TG has been demonstrated with increasingly higher doses of atorvastatin 28) .
Study Limitations
There are potential limitations regarding the interpretation of these results. First, the relatively small number of patients eligible for analysis in this study makes it difficult to generalize or to apply the results to other patient populations. Second, this was not a prospective, randomized, or double-blind study. Further head-to-head comparative trials are required to clarify the effect of pitavastatin as an antilipemic medication.
In conclusion, pitavastatin 1 mg was equipotent to atorvastatin 10 mg in regard to reducing LDL cholesterol levels. Both treatments were well tolerated.
